GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of small win: Canada stopped being a problem at week 30 — 11 comments in the full submission. View in context.
65
c/glp1canada·submitted 3 months ago by u/a1c_arc

small win: Canada stopped being a problem at week 30

Private Planbranch of 6 comments

Something I noticed reading old threads that I have not seen said out loud. The advice on special authorization in this community changed substantially around the start of last year, and nobody went back and updated the older posts. So depending on which thread the search engine hands you, you get two contradictory…

Read the full submission and all 11 comments →

This branch

6 comments, started 3 months ago
u/oskar_kaufmann12 points·3 months ago

Yeah, Canada coverage is not Canada coverage.

replysharereportpermalink
u/first_pen_fear-34 points·3 months ago

private plan details: redact your group number

replysharereportpermalink
u/kian_ekstrom1 point·3 months ago

private plan details: redact your group number

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

replysharereportpermalink
u/zeynep_duarte1 point·3 months ago

special authorization is the cross-province difference

replysharereportpermalink
[deleted]6 points·3 months ago

[deleted]

replysharereportpermalink
u/rina_nascimento5 points·3 months ago

cross-border pricing arbitrage is private plan but risky

replysharereportpermalink

← back to the whole thread

About c/glp1canada

Canadian access: provincial formulary differences, private plan coverage, the special-authorisation process, cross-border pricing arbitrage and why the Ontario answer is not the Alberta answer.

17kmembers
62submissions
Apr 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/glp1canada rules
  1. Name your province. Coverage is provincial.
  2. Private plan details: redact your group number.
  3. No cross-border purchasing instructions.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.